RecruitingNCT05100069

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

General Use-results Survey of Alunbrig Tablets "Non-small Cell Lung Cancer"


Sponsor

Takeda

Enrollment

500 participants

Start Date

Nov 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.


Eligibility

Interventions

DRUGBrigatinib

Brigatinib Tablets


Locations(1)

Takeda Selected Site

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05100069


Related Trials